Positive Outlook for Indaptus Therapeutics Amid Promising Clinical Trial Advancements and Innovative Decoy20 Platform

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Indaptus Therapeutics (INDP – Research Report). The associated price target was lowered to $2.00.

Jason McCarthy’s rating is based on Indaptus Therapeutics’ promising advancements in their clinical trials, particularly the ongoing P1b/2 study of Decoy20 in combination with the PD-1 inhibitor, tislelizumab. The company has shown positive data from the dose escalation phase, indicating favorable safety and broad immune responses, which supports the potential efficacy of their approach.
Furthermore, Indaptus’ innovative Decoy20 platform, which utilizes a bacterial-based immune induction method, represents a next-generation adaptation of historical cancer treatments. This approach, which significantly reduces toxicity while maintaining immune activation, is seen as a promising avenue for treating various cancers. The valuation model, which considers the mechanism of action and preclinical studies, supports a positive outlook with a 12-month price target of $2.00, despite the need for additional capital in the near term.

INDP’s price has also changed dramatically for the past six months – from $1.125 to $0.423, which is a -62.40% drop .